Kickback: The 10 biggest stories you might have missed on Stockhead this week
Link copied to
Many of our most popular stories this week are on COVID-19 (shocker) and ways to navigating a panic stricken market, but we’ve sprinkled a few non-doomsday stories in there for you. You’re welcome, happy Friday the 13th.
So you’re planning to buy the dip, maybe leverage up a bit to grab a bit more of that expensive blue chip than you could with whatever you’ve got stashed in the bank?
Past experience says curb that enthusiasm.
It can take a long time for share prices to fully bottom out once a crisis begins to unravel.
There are numerous vaccines, antiretrovirals and supportive therapies being feverishly tested against COVID-19 right now.
Past experience with SARS, MERS, H1N1 and Swine flu, new tech, and more funding all suggest vaccine development could be quicker this time.
Israeli researchers reckon they could have a vaccine in just 90 days. The University of Queensland in January said it could have a vaccine on the market within six months using a new technology. German biotech Curevac says 12 months, while US-based Inoiva Pharmaceuticals expects to have 1 million doses available by the end of the year.
As coronavirus spreads, much uncertainty still abounds as to 1) just how deadly is and 2) how fast it’s spreading. But out of nowhere, another negative catalyst emerged — an unexpected price war in global oil markets.
The result? Oil prices promptly crashed by 30 per cent — an almost unprecedented fall that sent shockwaves through global markets.
Right now, investors assessing portfolio risk need to make decisions based on a limited amount information.
And things are changing fast, which is why analysts at McKinsey & Co have assessed the potential COVID-19 fallout for markets based on three scenarios.
As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about COVID-19 but sadly not another ‘c’ word: cure.
The virus may fizzle out, like SARS did, but right now we need the best and brightest minds in the labs to come up with a treatment or — more likely — a vaccine.
(While we’re on it, we implore folk to stop hoarding toilet paper: after all, it’s the coronavirus, not the “Caroma-virus”.)
Other than gold and iron ore, things are pretty glum in the broader mining market right now.
This widespread volatility to the downside is nothing new to the decimated uranium sector.
But while the (spot) uranium price continues to struggle at less than $US25/lb ($38/lb), confidence is brewing that the long-promised uranium renaissance is upon us.
This episode features Tim Harrison, project manager for Oro Verde (ASX:OVL), which recently expanded its focus with the acquisition of a 20 per cent interest in the Makuutu rare earths project in Uganda.
Sh&t has gotten darker since we wrote this story but the fact remains — investors were still rewarding the best battery metals development stories, even as pricing circled the proverbial drain.
Here’s a list of five advanced ASX-listed lithium explorers — who aren’t exposed to prevailing low prices — who were making appreciable gains in 2020.
Mineral-rich Papua New Guinea boasts some of the biggest copper-gold mining operations in the world.
The advanced 20.5moz gold, 12.7mt copper Freida River development is just one example of how big these things can still get.
And while PNG hosts major miners such as Newcrest Mining (ASX:NCM) and Barrick Gold, there are also several ASX small caps searching for the next big company-maker.
Of the over 2100 stocks listed on the Australian bourse, 1654 are small caps with a market cap of less than $500m.
It’s not all that common for small cap stocks to pay a dividend. Of those 1654, less than 2 per cent — or just 29 stocks — actually distribute profits back to shareholders on the reg.